<DOC>
	<DOCNO>NCT01240941</DOCNO>
	<brief_summary>This phase II Trial MK-2206 combination Endocrine Therapy patient Hormone Receptor Breast Cancer . After maximum tolerate dose determined phase 1b trial ( separate NCT number ) , efficacy evaluate among 17 patient .</brief_summary>
	<brief_title>Trial MK-2206 + Endocrine Treatment Patients With Hormone Receptor Positive Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Goserelin</mesh_term>
	<mesh_term>Exemestane</mesh_term>
	<criteria>1 . Patient must clinical stage IV invasive mammary carcinoma , previously document histological analysis , ERpositive and/or PRpositive immunohistochemistry ( IHC ) , previous endocrine therapy metastatic setting metastatic recurrence within 6 month adjuvant endocrine therapy . Patients may either measurable nonmeasurable disease , allow . Any number prior hormone chemotherapy agent acceptable . 2 . Patient female great equal 18 year age day signing inform . consent 3 . Patient must performance status 0 1 ECOG Performance Scale . 4 . Patient must adequate organ function indicate follow laboratory value : Hematological : Absolute neutrophil count ( ANC ) great equal 1,500 /μL Platelets great equal 100,000 /μL Hemoglobin great equal 9 g/dL Renal : Serum creatinine calculate creatinine clearance† less equal 1.5 x upper limit normal ( ULN ) OR great equal 60 mL/min patient creatinine level great 1.5 x institutional ULN Hepatic : Serum total bilirubin less equal 1.5 x ULN OR direct bilirubin less equal ULN patient total bilirubin level great 1.5 x ULN AST ( SGOT ) ALT ( SGPT ) less equal 2.5 x ULN le equal 5 x ULN patient know liver metastasis Coagulation : Prothrombin time ( PT ) /INR less equal 1.2 x ULN Partial thromboplastin time ( PTT ) less equal 1.2 x ULN Metabolic HBA1C less equal 8 % † Creatinine clearance calculate per institutional standard . ‡ Fasting define least 8 hour without oral intake . 5 . Female patient childbearing potential must negative serum urine pregnancy test βhCG within 72 hour prior receive first dose study medication . 6 . Postmenopausal female subject define prior protocol enrollment follow : Subjects least 55 year age Subjects 55 year age amenorrheic least 12 month folliclestimulating hormone ( FSH ) value great equal 40 IU/L estradiol level less equal 20IU/L Prior bilateral oophorectomy prior radiation castration amenorrhea least 6 month 7 . Patient , patient 's legal representative , voluntarily agree participate give write informed consent . 8 . Patient able swallow capsule surgical anatomical condition preclude patient swallow absorb oral medication ongoing basis . 9 . Patients may receive concurrent radiation therapy painful bone metastasis area impend bone fracture long radiation therapy initiate prior study entry . Patients receive prior radiotherapy must recover toxicity induce treatment ( toxicity grade le equal 1 ) . 10 . Patients must diseasefree prior invasive cancer great 5 year exception basal squamous cancer skin cervical carcinoma situ . 1 . Patient chemotherapy , radiotherapy , biological therapy within 3 week ( 6 week nitrosoureas , mitomycin C bevacizumab ) , recover adverse event due previous agent administer 4 week prior Study Day 1 . If patient residual toxicity prior treatment , toxicity must less equal Grade 1 . 2 . Patients must least 4 week post major surgical procedure , surgical wound must fully heal . 3 . Patient currently participate participate study investigational compound device within 30 day Study Day 1 . 4 . Patient know active CNS metastasis and/or carcinomatous meningitis . However , patient CNS metastasis complete course therapy would eligible study provide clinically stable least 1 month prior entry define : ( 1 ) evidence new enlarge CNS metastasis ( 2 ) steroid use minimize surround brain edema . 5 . Patient primary central nervous system tumor . 6 . Patient known hypersensitivity component study drug analog . 7 . Patient history current evidence clinically significant heart disease include : Clinically significant congestive heart failure , unstable angina pectoris , Clinically significant cardiac arrhythmia , history current evidence myocardial infarction last 6 month , and/or current ECG trace abnormal opinion treat Investigator . Baseline QTc prolongation great 450 msec ( Bazett 's Formula ) . Medications include Arizona CERT Lists 1 2 ( Appendix D ) must exclude . The concomitant use drug associate increase risk QT prolongation avoid patient congenital long QT syndrome ( Appendix D , Arizona CERT List 3 ) . Similarly , concomitant use drug weakly associate QT prolongation generally avoid ( Appendix D , Arizona CERT List 4 ) . Arizona CERT List 3 4 drug use discretion Investigator restrict applicable . Any therapy give drug use caution , patient receive medication carefully monitor . 8 . Patient evidence clinically significant bradycardia ( heart rate le 50 ) , history clinically significant bradyarrhythmias sick sinus syndrome , 2nd degree AV block ( Mobitz Type 2 ) , patient take beta blocker , nondihydropyridine calcium channel blocker , digoxin . 9 . Patient uncontrolled hypertension ( i.e. , 160/90 mHg SiBP ) . Patients control antihypertensive medication allow enter study . 10 . Patient significant risk hypokalemia ( e.g. , patient high dose diuretic , recurrent diarrhea ) . 11 . Patient poorly control diabetes define HbA1C great 8 % . 12 . Patient history current evidence condition , therapy , lab abnormality might confound result study , interfere patient 's participation full duration study , best interest patient participate , opinion treat Investigator . 13 . Patient know psychiatric substance abuse disorder would interfere cooperation requirement trial . 14 . Patient , time signing informed consent , regular user ( include `` recreational use '' ) illicit drug recent history ( within last year ) drug alcohol abuse . 15 . Patient pregnant breastfeeding , expect conceive father child within project duration study . 16 . Patient known Human Immunodeficiency Virus ( HIV ) positive 17 . Patient known history Hepatitis B C active Hepatitis A . 18 . Patient symptomatic ascites pleural effusion . A patient clinically stable follow treatment condition eligible . 19 . Patient receive treatment oral corticosteroid ( note : inhaled corticosteroid permit ) .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2013</verification_date>
</DOC>